News / Events
Drug Dev. Team
Board of Directors
Drug Development Team
William D. Kerns, DVM, MS, DACVP, VP Drug Development
Dr. Kerns has over 20 years of experience in Pharmaceutical Research and Development at SmithKline Beecham and Eisai Pharmaceuticals. As a Senior Executive he has participated in the development of drugs for over 100 Phase I studies and 13 NDAs/MAAs. Bill has chaired a FDA committee on biomarkers and he is an expert in preclinical development and regulatory strategy.
Michael Silverman, MD, Medical Director
Dr. Silverman has extensive experience in clinical development acquired through his involvement in clinical development in large pharmaceutical and small biopharmaceutical companies. He was involved in international clinical research, market-oriented strategic planning, and the challenges of managing an R&D portfolio in various capacities in Sterling Winthrop Research Institute and subsequently in Sandoz Research Institute.
Zivit Harpaz, MA, Director of Regulatory and Clinical Operations
Zivit Harpaz gained her M.A. at the Haifa University, Israel. She has over 6 years of experience in Clinical Trial Management where she has led the logistic and monitoring affairs of Phase I/II, Phase II and Phase III clinical studies in the fields of Oncology, Ophthalmic and autoimmune Inflammatory Diseases.
Shira Cohen, M.Sc., Director of Molecular Biology Labs
Shira Cohen is a graduate of the Bar-Ilan University, Israel. She has 10 years of experience in basic and applied research in the field of autoimmunity and tumor immunology. Her research relating to ligands which bind to the A3 adenosine receptor contributed a lot to their translation into drug candidates, currently in advanced human clinical studies.